Equities research analysts expect Flexion Therapeutics Inc (NASDAQ:FLXN) to report earnings of ($1.06) per share for the current quarter, according to Zacks. Three analysts have made estimates for Flexion Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.08) and the highest estimate coming in at ($1.04). Flexion Therapeutics posted earnings per share of ($1.16) during the same quarter last year, which indicates a positive year-over-year growth rate of 8.6%. The business is expected to issue its next quarterly earnings results on Tuesday, August 6th.
On average, analysts expect that Flexion Therapeutics will report full-year earnings of ($4.07) per share for the current year, with EPS estimates ranging from ($4.18) to ($3.93). For the next financial year, analysts expect that the company will report earnings of ($2.44) per share, with EPS estimates ranging from ($2.95) to ($1.68). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Flexion Therapeutics.
Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.09) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.13) by $0.04. Flexion Therapeutics had a negative net margin of 549.07% and a negative return on equity of 131.94%. The business had revenue of $10.56 million for the quarter, compared to analyst estimates of $11.10 million.
FLXN has been the topic of several analyst reports. Zacks Investment Research upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, January 24th. BidaskClub upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, January 31st. Northland Securities restated a “buy” rating and issued a $20.00 price objective on shares of Flexion Therapeutics in a report on Friday, March 1st. Raymond James restated a “buy” rating on shares of Flexion Therapeutics in a report on Thursday, March 28th. Finally, Wells Fargo & Co restated a “buy” rating on shares of Flexion Therapeutics in a report on Wednesday, April 10th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. Flexion Therapeutics has an average rating of “Buy” and a consensus target price of $23.71.
NASDAQ FLXN traded down $0.74 during trading hours on Friday, hitting $12.52. The company’s stock had a trading volume of 493,123 shares, compared to its average volume of 609,455. Flexion Therapeutics has a twelve month low of $9.65 and a twelve month high of $29.10. The firm has a market capitalization of $475.67 million, a P/E ratio of -2.79 and a beta of 1.56. The company has a debt-to-equity ratio of 2.10, a current ratio of 6.32 and a quick ratio of 6.06.
In other news, CFO David Arkowitz bought 4,000 shares of the business’s stock in a transaction on Monday, May 13th. The shares were bought at an average cost of $11.99 per share, for a total transaction of $47,960.00. Following the completion of the acquisition, the chief financial officer now owns 86,924 shares in the company, valued at approximately $1,042,218.76. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Michael D. Clayman bought 4,012 shares of the business’s stock in a transaction on Friday, May 10th. The stock was purchased at an average price of $12.48 per share, for a total transaction of $50,069.76. Following the completion of the acquisition, the insider now owns 74,868 shares of the company’s stock, valued at approximately $934,352.64. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 12,058 shares of company stock worth $148,038. Company insiders own 16.01% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlueMountain Capital Management LLC bought a new stake in shares of Flexion Therapeutics during the 1st quarter worth about $215,000. Macquarie Group Ltd. boosted its holdings in shares of Flexion Therapeutics by 1.3% during the 1st quarter. Macquarie Group Ltd. now owns 69,379 shares of the specialty pharmaceutical company’s stock worth $866,000 after buying an additional 895 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Flexion Therapeutics by 5.9% during the 1st quarter. Geode Capital Management LLC now owns 407,174 shares of the specialty pharmaceutical company’s stock worth $5,081,000 after buying an additional 22,741 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Flexion Therapeutics by 3.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 187,896 shares of the specialty pharmaceutical company’s stock worth $2,345,000 after buying an additional 5,489 shares during the period. Finally, Gagnon Securities LLC boosted its holdings in shares of Flexion Therapeutics by 171.2% during the 1st quarter. Gagnon Securities LLC now owns 688,271 shares of the specialty pharmaceutical company’s stock worth $8,590,000 after buying an additional 434,448 shares during the period. Institutional investors own 94.96% of the company’s stock.
About Flexion Therapeutics
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Featured Article: What is Net Asset Value (NAV)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.